Evidence map›Paper›PMID 41036900›Full record

ArticleRevista da Sociedade Brasileira de Medicina Tropical2025

Managing leprosy reactions with secukinumab: Insights from a case series.

Luciana Vilela Gomide, João Paulo Turri Brufatto, Thiago Jessé Kucarz, Paulo Eduardo Neves Ferreira Velho, Andréa Fernandes Eloy da Costa França

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Revista da Sociedade Brasileira de Medicina Tropical, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Luciana Vilela GomideUniversidade Estadual de Campinas, Faculdade de Ciências Médicas, Campinas, SP, Brasil.ORCID http://orcid.org/0009-0001-5465-5462
João Paulo Turri BrufattoUniversidade Estadual de Campinas, Faculdade de Ciências Médicas, Campinas, SP, Brasil.ORCID http://orcid.org/0000-0001-9752-377X
Thiago Jessé KucarzUniversidade Estadual de Campinas, Faculdade de Ciências Médicas, Campinas, SP, Brasil.ORCID http://orcid.org/0009-0000-7339-3026
Paulo Eduardo Neves Ferreira VelhoUniversidade Estadual de Campinas, Faculdade de Ciências Médicas, Campinas, SP, Brasil.ORCID http://orcid.org/0000-0001-7901-2351
Andréa Fernandes Eloy da Costa FrançaUniversidade Estadual de Campinas, Faculdade de Ciências Médicas, Campinas, SP, Brasil.ORCID http://orcid.org/0000-0003-1657-4570

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundErythema nodosum leprosum (ENL) is an immunological inflammatory reaction requiring precise management. Recalcitrant cases, their refractoriness to conventional therapy, and the adverse effects of standard treatments underline the need to explore alternative therapeutic options.

methodsWe conducted a retrospective study of five patients treated with secukinumab between January 2023 and January 2025.

resultsPatients showed clinical improvement with a reduced ENL frequency, neuritis relief, and corticosteroid sparing.

conclusionsSecukinumab appears to be a promising corticosteroid-sparing option for ENL, with a favorable safety profile. Further studies are required to confirm the efficacy and long-term safety of this treatment regimen.

Indexed as

Antibodies, Monoclonal, HumanizedErythema NodosumLeprosy, LepromatousHumansRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, Humanizedsecukinumab

Identifiers

PMID41036900
PMCPMC12479038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.